Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273262 | 0.84 | ADORA3 (0.53) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4262285 | 0.81 | MCL1 (0.49) | LTB4RMAPK1 | |
| SCHEMBL5269568 | 0.81 | PLA2G2A (0.48) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4263343 | 0.80 | MCL1 (0.52) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4267571 | 0.79 | P2RY12 (0.45) | LTB4RMAPK1 | |
| SCHEMBL4267147 | 0.78 | MEN1 (0.45) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4264891 | 0.77 | TLR8 (0.49) | ADORA1ADORA2ALTB4RMAPK1 | |
| SCHEMBL13931514 | 0.71 | ADORA1 (0.48) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4268096 | 0.69 | ADORA1 (0.55) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4260774 | 0.69 | ADORA1 (0.77) | ADORA1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | ADORA1 570/4885ADORA3 591/4885ADORA2A 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.